

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Anker Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : ACS / AMI (2010)</li> <li>- Boehringer-Ingelheim : Anti-coagulation in CV disease (2010)</li> <li>- Bayer AG : Anti-coagulation in heart failure (2011)</li> <li>- BRAHMS GmbH : Biomarker Heart Failure (2010)</li> <li>- BRAHMS GmbH : Biomarker in heart failure (2011-2012)</li> <li>- BG medicine : Biomarker in heart failure (2011-2012)</li> <li>- Abbott Laboratories : Biomarker Renal Failure (2010)</li> <li>- Astra Zeneca : Cachexia therapy (2010)</li> <li>- Novartis : Cachexia therapy (2010-2011-2012)</li> <li>- GSK : Cachexia therapy (2011-2012)</li> <li>- GTx : Cachexia therapy (2011-2012)</li> <li>- Myotec Therapeutics : Cachexia therapy in cancer (2010)</li> <li>- PsiOxus Therapeutics : Cachexia therapy in cancer (2011-2012)</li> <li>- Reata : CKD therapy (2011)</li> <li>- Abbott Vascular : Device heart failure (2012)</li> <li>- Impulse Dynamics : Device in heart failure (2011)</li> <li>- Impulse Dynamics : Device in heart failure (2012)</li> <li>- LoneStar Heart : Device in heart failure (2011-2012)</li> <li>- Abbott Vascular : Device Renal Failure (2011)</li> <li>- Pluristem Therapeutics : DSMB - stem cells for muscle wasting (2012)</li> <li>- Applied Clinical Intelligence, LLC : Endpoint adjudication COPD (2011-2012)</li> <li>- Nanosphere : FAST-TRAC (2010)</li> <li>- Servier : Heart failure (2012)</li> <li>- Menarini : Heart failure (2012)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Anker Stefan	<ul style="list-style-type: none"> <li>- Cardiomems : Heart failure (2012)</li> <li>- Bayer AG : Heart failure (2012)</li> <li>- Medical Sensible : Heart failure (2012)</li> <li>- Vifor International : iv Iron therapy for heart failure (2010-2011-2012)</li> <li>- Servier : Ivabradine heart failure (2011)</li> <li>- Relypsa : K+ Resin (2010-2011-2012)</li> <li>- Professional Dietetics / Solartium Dietetics GmbH : Nutrition for Muscle Wasting / Cachexia (2012)</li> <li>- Professional Dietetics / Solartium Dietetics GmbH : Nutrition for Muscle Wasting / Cachexia (2010-2011)</li> <li>- Fresenius Nutrition : Pre-Cachexia therapy (2010-2011)</li> <li>- Amgen Inc : RED-HF (2010)</li> <li>- Amgen Inc : RED-HF (2011)</li> <li>- Novartis : SAB heart failure (2012)</li> <li>- Amgen Inc : SAB heart failure (2012)</li> <li>- St Jude Medical : Telemonitoring (2010-2011-2012)</li> <li>- Bosch AG Germany : Telemonitoring (2011-2012)</li> <li>- SHL Telemedicine : Telemonitoring (2011)</li> <li>- Bosch AG Germany : TIM-HF (2010)</li> <li>- Cardiorentis : TRUE-AHF trial, executive committee (2012)</li> <li>D - Research funding (departmental or institutional). <ul style="list-style-type: none"> <li>- BRAHMS GmbH : Biomakers (2010)</li> <li>- BRAHMS GmbH : Biomakers in heart failure (2011)</li> <li>- Metabolic Research srl (Italy) : Cachexia nutrition research (2012)</li> <li>- Novartis : cachexia research (2012)</li> <li>- Myotec Therapeutics : Cancer cachexia (2010)</li> <li>- PsiOxus Therapeutics : Cancer cachexia (2011-2012)</li> </ul> </li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - TF Members and Additional Contributors

Expert	Type of Relationship with Industry
Anker Stefan	<ul style="list-style-type: none"> <li>- Novartis : CHF therapy development (2011)</li> <li>- Vifor International : CHF therapy development (2011-2012)</li> <li>- Bayer AG : CHF therapy development (2011-2012)</li> <li>- Impulse Dynamics : Heart failure (2012)</li> <li>- Abbott Vascular : Heart failure (2012)</li> <li>- Medical Sensible : Heart failure (2012)</li> <li>- Abbott Nutrition : Nutrition education (2011)</li> <li>- Fresenius Nutrition : Pre-cachexia CHF / COPD (2010)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Anker Stefan	<p>06/06/2013</p> <p>under A:</p> <p>BG Medicine</p> <p>Professional Dietetics / Solartium Dietetics GmbH: now no longer active</p> <p>Amgen Inc: now no longer active</p> <p>GSK: now no longer active</p> <p>Servier</p> <p>Janzen (J&amp;J) = new</p> <p>under D -- research funding</p> <p>PsiOxus: now no longer support</p> <p>Bayer</p> <p>Medical Sensible: now no longer support</p>
Berne Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Diabetes (2010-2011-2012)</li> <li>- Sanofi Aventis : Diabetes (2010-2011-2012)</li> <li>- Bayer Healthcare : Diabetes (2010-2011-2012)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Berne Christian	<ul style="list-style-type: none"> <li>- Astellas : Diabetes (2010-2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Diabetes (2010-2011-2012)</li> <li>- Novo-Nordisk : Diabetes (2010-2011-2012)</li> <li>- Bioarctic : Islet transplantation för diabetes (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>07/08/2013      No further information. August 7th 2013.</p>
Cosentino Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : CVD (2010-2011-2012)</li> <li>- Astra Zeneca : CVD (2010-2011-2012)</li> <li>- Chiesi Pharma : CVD (2010-2011-2012)</li> <li>- Takeda Pharmaceuticals : CVD (2010-2011-2012)</li> <li>- Sigma Tau : CVD (2011-2012)</li> <li>- F. Hoffman La Roche Ltd : CVD and T2DM (2010-2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Swiss Heart Foundation : CVD and T2DM (2011)</li> <li>- Swiss Heart Foundation : CVD and T2DM (2012)</li> <li>- Rome Foundation : CVD and T2DM (2010-2011)</li> <li>- University "Sapienza" of Rome : CVD and T2DM (2010-2011-2012)</li> <li>- Italian Ministry for University, Research and Education (PRIN) : CVD and T2DM (2012)</li> </ul> <p><b>Additional Information declared:</b></p>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Cosentino Francesco	15/05/2013 Please add Advisory Board fees MSD as of July 2013. No further changes to declare
Danchin Nicolas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : antianginal agents (2010-2011-2012)</li> <li>- Boehringer-Ingelheim : Antithrombotic agents (2010-2011-2012)</li> <li>- BMS/Pfizer : Antithrombotic agents (2010-2011-2012)</li> <li>- Medicines Company : Antithrombotic agents (2010-2011-2012)</li> <li>- Daiichi Sankyo, Eli-Lilly : Antithrombotic agents (2010-2011-2012)</li> <li>- Sanofi Aventis : antithrombotic agents, antiarrhythmic agents (2010-2011-2012)</li> <li>- Astra Zeneca : Antithrombotic agents, statins (2010-2011-2012)</li> <li>- Roche Pharma : Dalcetrapib (2011-2012)</li> <li>- Novo-Nordisk : Diabetes (2010-2011-2012)</li> <li>- Pierre-Fabre : Omega 3 (2010-2011-2012)</li> <li>- Bayer : Rivaroxaban (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Myocardial infarction (2010-2011-2012)</li> <li>- Sanofi Aventis : Myocardial infarction (2010-2011-2012)</li> <li>- GlaxoSmithKline : Myocardial infarction (2010-2011-2012)</li> <li>- Medicines Company : Myocardial infarction (2010-2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Myocardial infarction (2010-2011-2012)</li> <li>- Daiichi-Sankyo Eli Lilly : Myocardial infarction (2010-2011-2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013 AMGEN: consulting fees</p>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Deaton M Christi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- St Jude Medical : Cath lab - speaker X 1 (2010)</li> <li>- Daiichi Sankyo : consultant for patient adherence 2009-10 (2010)</li> <li>- Eli Lilly : consultant for patient adherence 2009-10 (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : medicines for diabetes (2010)</li> <li>- Novo-Nordisk : patients with heart failure and diabetes (2011-2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013      Funding from Novo Nordisk has ended, no other changes to report</p>
Escaned Javier	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Alvi Medical : Coronary stents (2012)</li> <li>- St Jude Medical : Intracoronary diagnostics (2012)</li> <li>- Volcano : Intracoronary diagnostics (2012)</li> <li>- Boston Scientific, St Jude Medical, Volcano : Intracoronary diagnostics (2011)</li> <li>- Boston Scientific : Intracoronary diagnostics, coronary stents (2012)</li> <li>- St Jude Medical : Pressure guidewire (2010)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Grant Peter J	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medicines Company : Bivalirudin (2010)</li> <li>- Bristol Myers Squibb : Gliptins for management of Type 2 Diabetes (2010)</li> <li>- Merck Sharp &amp; Dohme : Metformin in diabetes (2010)</li> <li>- Advisor to Synexus : No product, recruit patients into clinical trials (2012)</li> <li>- Synexus : Synexus recruit patients into clinical trials, they do not have a product. (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Lilly : Collaborator on a study of prasugrel in type 2 diabetes (2011)</li> <li>- Daiichi Sankyo : Prasugrel (2010)</li> <li>- Lilly : Prasugrel (2012)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>
Hammes Hans-Peter	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- GlaxoSmithKline : Antidiabetic (2010)</li> <li>- Astra Zeneca : Antihypertensive (2010)</li> <li>- Boehringer-Ingelheim : Diabetic Retinopathy - Linagliptin (2012)</li> <li>- Wörwag Pharma : Neurotrophin (2010)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Antidiabetic (2011)</li> <li>- Sanofi Aventis : Diabetic Retinopathy (2012)</li> <li>- Boehringer-Ingelheim : Antidiabetic (2010)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>
Huikuri Heikki	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Boehringer Ingelheim - Ingelheim; Daiichi-Sankyo/Eli Lilly; Nycomed Pharma : antithrombotic treatment of atrial fibrillation (2010-2011)</li> <li>- Sanofi Aventis : dronedarone in atrial fibrillation (2010-2011)</li> </ul>



## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Huikuri Heikki	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : vernakalant in atrial fibrillation (2010-2011)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medtronic : Refine-ICD study, prophylctic implantable cardioverter defibrillator (2011)</li> <li>- Medtronic : Refine-ICD study, prophylctic implantable cardioverter defibrillator (2012)</li> <li>- Boehringer Ingelheim - Ingelheim; Daiichi-Sankyo/Eli Lilly; Nycomed Pharma : research on antithrombotic treatment in atrial fibrillation (2010-2011-2012)</li> </ul> </li> </ul> <p><b>Additional Information declared:</b></p> <p>06/08/2013      No new information</p>
Marre Michel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antidiabetic drugs, boards, lectures (2010-2011-2012)</li> <li>- Novo-Nordisk : Antidiabetic drugs, boards, lectures (2010-2011-2012)</li> <li>- Eli Lilly : Boards (2010-2011-2012)</li> <li>- Servier : Boards, lectures (2010-2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Boards, lectures (2010-2011-2012)</li> <li>- Abbott : Devices for self monitoring of blood glucose (2010-2011-2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Clinical trials (2010-2011-2012)</li> <li>- Novartis : Clinical trials (2010-2011-2012)</li> <li>- Sanofi Aventis : Clinical trials (2010-2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Clinical trials (2010-2011-2012)</li> <li>- Novo-Nordisk : Not for therapeutic purpose (2010-2011)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Marx Nikolaus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Anticoagulants (2011-2012)</li> <li>- Medtronic : CV devices (2010-2011)</li> <li>- Cordis : CV devices (2011)</li> <li>- Sanofi Aventis-AVENTIS : CV, diabetes (2010-2011)</li> <li>- Sanofi-Aventis : CV, Diabetes (2012)</li> <li>- Astra Zeneca : Diabetes (2010-2011-2012)</li> <li>- Boehringer-Ingelheim : Diabetes (2010-2011)</li> <li>- Novartis : Diabetes (2010-2011-2012)</li> <li>- Sanofi Aventis : Diabetes (2010-2011)</li> <li>- Lilly : Diabetes (2011-2012)</li> <li>- Roche Pharma : Diabetes (2011-2012)</li> <li>- Bristol Myers Squibb : Diabetes (2012)</li> <li>- Merck Sharp &amp; Dohme : Diabetes (2010-2011-2012)</li> <li>- Novo-Nordisk : Diabetes (2012)</li> <li>- Novo-Nordisk : diabetes (2010-2011)</li> <li>- Boehringer-Ingelheim : Diabetes, CV (2012)</li> <li>- Boehringer-Ingelheim : Diabetes, CV (2010-2011)</li> <li>- Pfizer : Lipids (2010-2011)</li> <li>- Fournier Laboratories : Lipids (2012)</li> <li>- BMBF - German Ministry of Research and Education; DFG - German Research Foundation; IQWiG - Institute for Quality and Economic Viability in Health Service; DEGAM - German College of General Practitioners : Research (2010-2011)</li> <li>- DFG - German Research Foundation : Research (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Diabetes (2010-2011)</li> <li>- Boehringer-Ingelheim : Diabetes (2010-2011-2012)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Marx Nikolaus	<ul style="list-style-type: none"> <li>- Sanofi Aventis : Diabetes (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : Diabetes (2010-2011)</li> <li>- Novo-Nordisk : diabetes (2010-2011)</li> <li>- GlaxoSmithKline : diabetes; CV (2010)</li> <li>- Novartis : CV (2010)</li> <li>- BMBF - German Ministry of Research and Education; DFG - German Research Foundation; IQWiG - Institute for Quality and Economic Viability in Health Service; DEGAM - German College of General Practitioners : research (2010)</li> <li>- EASD : research (2010)</li> <li>E - Research funding (personal).               <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Diabetes (2011-2012)</li> <li>- EASD : diabetes (2010-2011-2012)</li> <li>- BMBF - German Ministry of Research and Education; DFG - German Research Foundation; IQWiG - Institute for Quality and Economic Viability in Health Service; DEGAM - German College of General Practitioners : research (2010-2011)</li> <li>- BMBF - German Ministry of Research and Education; DFG - German Research Foundation : Research (2012)</li> </ul> </li> </ul> <p><b>Additional Information declared:</b></p> <p>23/05/2013      Same relationships as declared for 2013 on 27.02.2013 i. e. no changes to declare</p> <p>05/08/2013      In addition to declaration of May 23rd, 2013:</p> <p style="padding-left: 40px;">Financial Declaration - B: Payment to your Institution:</p> <p style="padding-left: 40px;">- Amgen GmbH</p>
Mellbin Linda	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Diabetes and Cardiovascular disease (2010)</li> <li>- Bayer : Diabetes and Cardiovascular disease (2010)</li> <li>- Roche Pharma : Diabetes and Cardiovascular disease (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Diabetes and Cardiovascular disease (2010-2011-2012)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Mellbin Linda	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  - Roche Pharma : National coordinator, Investigator (2010-2011-2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Ostergren Jan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  - None</p> <p>D - Research funding (departmental or institutional).  - Novartis : Aliskiren (2011-2012)</p> <p><b>Additional Information declared:</b></p> <p>31/05/2013      No changes to declare for 2013</p>
Patrono Carlo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  - Bayer : Aspirin (2010-2011)  - Bayer : Aspirin (2012)  - NicOx : Naproxcinod (2010)  - Eli Lilly : Prasugrel (2010-2011-2012)  - Servier : Terutroban (2010)  - Astra Zeneca : Ticagrelor, PPI (2010-2011-2012)  - Merck Sharp &amp; Dohme : Vorapaxar (2010-2011-2012)</p> <p>D - Research funding (departmental or institutional).  - Bayer Schering Pharma : Aspirin (2010-2011)  - Bayer AG : Aspirin (2012)</p> <p><b>Additional Information declared:</b></p>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Patrono Carlo	14/05/2013 Same relationships as 2012, ie, no change to declare.
Ryden Lars	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Cardiology; Course organisation, lecture (2010-2011-2012)</li> <li>- Sanofi Aventis : Diabetes and cardiovascular disease. Advisor boards, lecture fees (2011)</li> <li>- BMS : Diabetes and cardiovascular disease. Advisory committee fee (2010-2011-2012)</li> <li>- Astra Zeneca : Diabetes and cardiovascular disease; Advisory Board and occasional lecture fees (2010-2011-2012)</li> <li>- Roche Pharma : Diabetes and cardiovascular disease; Consultant, lecture fees (2010-2011-2012)</li> <li>- Bayer : Diabetes and cardiovascular disease; Lecture fees (2012)</li> <li>- Bayer : Diabetes and cardiovascular disease; Lecture fees (2010-2011)</li> <li>- Amgen : Member DSMB (2010-2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Roche Pharma : Diabetes and cardiovascular disease (2012)</li> <li>- Astra Zeneca : Cardiology (2010-2011)</li> <li>- Roche Pharma : Cardiology (2010-2011)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013 I have become honorary member of the Moldavian and the Romanian Societies of Cardiology in April 2013.</p> <p>13/05/2013 Besides the new honorary memberships no further changes,</p> <p>31/07/2013 Nothing new -my declaration is still valid July 31 2013.</p>
Seferovic Petar	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : heart failure, hypertension (2010-2011-2012)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Seferovic Petar	<ul style="list-style-type: none"> <li>- Pfizer : heart failure, hypertension (2010-2011-2012)</li> <li>- Berlin Chemie AG : heart failure, hypertension (2010-2011-2012)</li> <li>- Richter Gedeon : hypertension (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2010-2011-2012)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>
Sousa Uva Miguel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Astra Zeneca : Ticagrelor (2011)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013      No New Information</p>
Taskinen Marja-Riitta	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Pharma : CETP inhibitor (2010-2012)</li> <li>- Merck Sharp &amp; Dohme : CETP inhibitor (Anacetrapid), Tredaptive (2011)</li> <li>- Merck Sharp &amp; Dohme : CETP inhibitor, tredaptive (2010)</li> <li>- Boehringer-Ingelheim : DDP4 inhibitor (2010)</li> <li>- Kowa : Pivastatin (2012)</li> <li>- Sanofi Aventis : Regeneron (2011)</li> <li>- Astra Zeneca : Statins (2011)</li> <li>- Kowa : Statins (2010-2011)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Taskinen Marja-Riitta	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : CETP inhibitor (2012)</li> <li>- Merck Sharp &amp; Dohme : CETP inhibitor (2010)</li> <li>- Merck Sharp &amp; Dohme : CETP-Inhibitor (Anacetrapid) (2011)</li> <li>- Takeda Pharmaceuticals : DDP4 inhibitor (2010)</li> <li>- Novartis : DPP-4 inhibitor, Vildagliptin (2011)</li> <li>- Eli Lilly : Exenatide (2010)</li> <li>- Novo-Nordisk : No product (2010)</li> <li>- Sanofi Aventis : PCSK9 anti-sense (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>06/08/2013      'same relationships as 2012 i.e. no changes to declare'</p>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin, Rivaroxaban (2011-2012)</li> <li>- Amgen : Darbopietin (2011-2012)</li> <li>- Servier : Ivabradine, Phase II investigational products (2011-2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2011-2012)</li> <li>- TIMI group : Rivaroxaban (2011)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013      No new info.</p>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Tuomilehto Jaakko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : diabetes (2010-2011)</li> <li>- Bayer Healthcare : diabetes (2010-2011-2012)</li> <li>- Novo-Nordisk : diabetes (2010-2011-2012)</li> <li>- Novartis : diabetes, hypertension (2010-2011)</li> <li>- Astra Zeneca : dyslipidaemia, diabetes (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : dyslipidaemia, hypertension, diabetes (2010-2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : coronary heart disease (2012)</li> <li>- Novartis : diabetes (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : dyslipidaemia (2010-2011-2012)</li> <li>- Sanofi-Aventis : dyslipidaemia, diabetes (2012)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Servier : coronary heart disease (2011-2012)</li> <li>- Astra Zeneca : diabetes (2010-2011)</li> <li>- Novo-Nordisk : diabetes (2010-2011)</li> <li>- Merck Sharp &amp; Dohme : dyslipidaemia (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>11/08/2013      No longer in the Board of the Finnish Hypertension Society</p>



## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Valensi Paul	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer Ingelheim : diabetes (2012)</li> <li>- Sanofi Aventis : diabetes, coronary disease (2012)</li> <li>- BMS : Diabetes, DPP4 inhibitors (2012)</li> <li>- Novartis : diabetes, DPP4 inhibitors (2012)</li> <li>- MSD : diabetes, DPP4 inhibitors (2012)</li> <li>- Novo Nordisk : diabetes, insulins (2012)</li> <li>- Abbott Laboratories : diabetes, lipids, cardiovascular risk (2012)</li> <li>- Lilly : diabetes, neuropathy (2012)</li> <li>- Sankey : diabetic neuropathy (2012)</li> <li>- Kowa : lipid lowering therapy (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- BMS : diabetes (2012)</li> <li>- Lilly : Diabetes (2012)</li> <li>- Novo Nordisk : diabetes (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>17/05/2013      same relationships as last year i.e. no changes to declare</p>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulation (2010)</li> <li>- Abbott Vascular : Help in Design Echocardiographic protocol (2012)</li> <li>- Philips : Imaging (2010)</li> </ul>

## Guidelines on CVD in Diabetes 2013 (TF24) - Task Force Members

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Lecture (2012)</li> <li>- Merck Sharp &amp; Dohme : Lipids (2010)</li> <li>- FP7 EU research program : CV Imaging (2012)</li> <li>- Abbott Vascular : IMAGING IN HF (2011)</li> <li>- Merck Sharp &amp; Dohme : LIPIDS (2011)</li> <li>- Springer : ESC Textbook of CV Imaging (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013      Same</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Alegria Ezquerro Eduardo	<p>None</p> <p><b>Additional Information declared:</b></p> <p>13/05/2013      Fees from Servier corresponding to CLARIFY Registry (local investigator)</p> <p>06/08/2013      No new changes to declare</p>
Avogaro Angelo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : GLP-1 agonists (2011-2012)</li> <li>- Sanofi Aventis : Insulin (2011-2012)</li> <li>- EASD : Investigator (2011-2012)</li> <li>- Astra Zeneca : Oral Hypoglycemic Agents (2011-2012)</li> <li>- Boehringer-Ingelheim : Oral Hypoglycemic Agents (2011-2012)</li> <li>- Novartis : Oral Hypoglycemic Agents (2011-2012)</li> <li>- Servier : Oral Hypoglycemic Agents (2011-2012)</li> <li>- GlaxoSmithKline : Oral Hypoglycemic Agents (2011-2012)</li> <li>- Bristol Myers Squibb : Oral Hypoglycemic Agents (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Oral Hypoglycemic Agents (2011-2012)</li> <li>- Sigma Tau : Oral Hypoglycemic Agents (2011-2012)</li> <li>- TIMI group : SAVOR Study (2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- EASD : Oral Hypoglycemic Agents (2011-2012)</li> </ul> <p><b>Additional Information declared:</b></p>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Avogaro Angelo	14/05/2013 I have no changes as compared to the previous DOI.
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : cardiovascular (2011-2012)</li> <li>- Menarini : cardiovascular (2012)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2011-2012)</li> <li>- Recordati International : cardiovascular (2011)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013 Relationships as 2012 i.e. no changes to declare.</p>
Baranova Elena	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Dabidatran (2012)</li> <li>- Abbott : Moxonidin (2012)</li> <li>- Abbott : Moxonidine (2011)</li> <li>- Servier : Speaker fees: Perindopril (2012)</li> <li>- Servier : Perindopril (2011)</li> <li>- Boehringer-Ingelheim : dabigotran (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novartis : RAAS blocker (2012)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Baumgartner Helmut	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013      no changes compared to 2012</p>
Betteridge John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Lipids (2011-2012)</li> <li>- Astra Zeneca : Lipids (2011-2012)</li> <li>- Eli Lilly : Lipids (2011-2012)</li> <li>- Pfizer : Lipids (2011-2012)</li> <li>- Roche Pharma : Lipids (2011-2012)</li> <li>- Schering-Plough : lipids (2011-2012)</li> <li>- Kowa : Lipids (2011-2012)</li> <li>- Recordati International : Lipids (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Lipids and diabetes (2011-2012)</li> <li>- Takeda Pharmaceuticals : Lipids diabetes (2011-2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>15/05/2013      There has been no change in conflicts</p>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Ceriello Antonio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Diabetes (2011-2012)</li> <li>- BMS : Diabetes (2011-2012)</li> <li>- Boehringer-Ingelheim : Diabetes (2011-2012)</li> <li>- Eli Lilly : Diabetes (2011-2012)</li> <li>- F. Hoffman La Roche Ltd : Diabetes (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Diabetes (2011-2012)</li> <li>- Bayer Schering Pharma : Diabetes (2011-2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>20/05/2013 "same relationships as last year i.e. no changes to declare"</p>
De Backer Guy	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Advisory board (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Advisory board (2011)</li> <li>- MSD : Advisory board (2012)</li> <li>- Abbott : member of publication committee POWER study (2011)</li> </ul> <p><b>Additional Information declared:</b></p> <p>06/08/2013 No changes to declare</p>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Fagard Robert	<p>None</p> <p><b>Additional Information declared:</b></p> <p>07/08/2013      No changes to declare</p>
Funck-Brentano Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis CH : Adjudication Committee on an immunosuppressant (2011-2012)</li> <li>- Lundbeck : Cardiac safety of an antidepressant (2011-2012)</li> <li>- Shire HGT : Cardiac safety of an antidiarrheal drug (2012)</li> <li>- Pierre-Fabre : Cardiac Safety of non-cardiovascular products (2011-2012)</li> <li>- Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012)</li> <li>- Johnson &amp; Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. (2011-2012)</li> <li>- MMV (CH) : Cardiac Safety of an antimalarial drug (2011)</li> <li>- Santhera (CH) : Cardiac Safety of an antimalarial drug (2011)</li> <li>- Sigma Tau : Cardiac Safety of an antimalarial drug (2011)</li> <li>- MMV (CH) : Cardiac Safety of two antimalarial drugs (2012)</li> <li>- Actelion : Consulting on the potential development of a calcium inhibitor (2012)</li> <li>- BMS : Discussion on an educational program for stroke prevention in AF (2012)</li> <li>- TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis – Cardiac safety (2011)</li> <li>- CEPHALON : DSMB in an oncology phase IIb trial (2011-2012)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Funck-Brentano Christian	<ul style="list-style-type: none"> <li>- Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel (2011)</li> <li>- Intracellular Therapies USA : Psychotropic drug development (2011)</li> <li>- Medco Health Solutions : co-investigator of a phase I study of an iv antiplatelet drug - payment to the hospital (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>26/05/2013      No new info since my DOI of 27/02/2013</p> <p>30/07/2013      Personal consultant contract with MEDA France Scope : PK variability of Flecainide SR</p>
Gulba Dietrich CI	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- The Medicines Company (TMC) : Bivalirudin (2012)</li> <li>- Boehringer-Ingelheim : Dabigatran (2012)</li> <li>- Daiichi Sankyo : Prasugrel (2012)</li> <li>- Eli Lilly : Prasugrel (2012)</li> <li>- Bayer Vital : Rivaroxaban, (2012)</li> <li>- Astra Zeneca : Ticagrelor (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>07/08/2013      All of my financial disclosures belong to Category A and are direct payments for speakers honaria or my service in advisory boards. I currently do not receive any honaria to my institution nor royalties nor receive any research funding from any company. I am investigator in only one phase VI trial for Ximelagatran (official Sponsor is Bayer). The revenue goes to my institution</p>
Hoes Arno	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> </ul>



## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Hoes Arno	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</li> <li>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012)</li> <li>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>03/06/2013      no changes to declare</p>
Kjekshus John Karsten	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Anacetrapib (2012)</li> <li>- TIMI Study Group , Boston USA : Clinical trials Niacin laropiprant (2012)</li> <li>- Novartis : Heart transplantation (2011)</li> <li>- Servier : Ivabradine (2011-2012)</li> <li>- TIMI group : Lipid modification (2011)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
	<p><b>Additional Information declared:</b></p> <p>14/05/2013      There is no change regarding Financial Interests or Positions of Influence which might impact your ESC activities during the current year. In other words: No conflict of interest</p> <p>14/08/2013      No change</p>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012)</p> <p>D - Research funding (departmental or institutional). - Servier : Vascular inflammation (2012) - Athera : vascular inflammation (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet agents (2012) - Regado Biosciences : Antithrombotic agents (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2012)</p> <p>D - Research funding (departmental or institutional). - Edwards Lifesciences : Cardiac valves (2012) - Medtronic : Cardiac valves (2012) - St Jude Medical : Cardiac valves (2012) - Boston Scientific : Coronary stents (2012) - Siemens Healthcare : Medical imaging (2012) - Johnson &amp; Johnson : Thoracoscopic devices (2012)</p> <p><b>Additional Information declared:</b></p> <p>15/05/2013      same relationships as 2012 i.e. no changes to declare</p>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Lev Eli	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Apixaban (2012)</li> <li>- Eli Lilly : Prasugrel (2012)</li> <li>- Astra Zeneca : Speakers Fees + Advisory board fees (2011)</li> <li>- Eli Lilly : Speakers Fees + Advisory board fees (2011)</li> <li>- Astra Zeneca : Ticagrelor (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>06/08/2013      No changes to declare</p>
Mueller Christian	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Acute Heart FAilure (2011-2012)</li> <li>- BRAHMS GmbH : Diagnostics (2011-2012)</li> <li>- Alere : Diagnostics (2011-2012)</li> <li>- Roche Diagnostics : Diagnostics (2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medicines Company : Acuet Heart FAilure (2011-2012)</li> <li>- BRAHMS GmbH : Diagnostics (2011-2012)</li> <li>- Swiss Heart Foundation : Diagnostics (2011-2012)</li> <li>- Beckman Coulter : Diagnostics (2011-2012)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Mueller Christian	<ul style="list-style-type: none"> <li>- Nanosphere : Diagnostics (2011-2012)</li> <li>- Abbott Laboratories : Diagnostics (2011-2012)</li> <li>- Roche Diagnostics : Diagnostics (2011-2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013      no changes to declare</p>
Neyses Ludwig	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Medical Research Council, UK : heart failure research (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>12/08/2013      No new information to declare</p>
Nilsson Peter M	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novo Nordisk : Diabetes treatment (2011-2012)</li> <li>- Boehringer-Ingelheim : linagliptin (2011-2012)</li> <li>- Asstrazeneca : Saxagliptin (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : sitagliptin, anacetrapib (2011-2012)</li> <li>- Novartis : Vildagliptin (2011-2012)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Nilsson Peter M	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : vildagliptin (2011-2012)</p> <p><b>Additional Information declared:</b></p> <p>14/05/2013      'I have the same relationships as 2012 i.e. no changes to declare</p> <p>,</p>
Perk Joep	<p>None</p> <p><b>Additional Information declared:</b></p> <p>No additional information for the 2013 January - August period was submitted</p>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : anticoagulant (2012)</li> <li>- Boehringer-Ingelheim : anticoagulant (2012)</li> <li>- Respicardia : anticoagulant (2012)</li> <li>- Abbott Vascular : devices (2012)</li> <li>- Amgen : heart failure (2012)</li> <li>- Novartis : heart failure (2012)</li> <li>- Johnson &amp; Johnson : heart failure (2012)</li> <li>- Bayer Healthcare : heart failure (2012)</li> <li>- Vifor Pharma Ltd : heart failure (2012)</li> <li>- Corthera : heart failure (2012)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Coridea : heart failure (2012)</li> <li>- Pfizer : heart failure, anticoagulant (2012)</li> <li>- Servier : heart failure, coronary artery disease (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vifor Pharma ltd : heart failure (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013      update to DOI 2012: - Abbott Vascular</p>
Reiner Zeljko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : anticoagulants (2011)</li> <li>- Astra Zeneca : antilipemics (2011-2012)</li> <li>- Pfizer : antilipemics (2011)</li> <li>- Sanofi Aventis : antilipemics (2011)</li> <li>- Abbott Laboratories : antilipemics (2011-2012)</li> <li>- Bayer : Antithrombotics (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Antilipemics (2012)</li> <li>- Merck Sharp &amp; Dohme : Antilipemics (2012)</li> <li>- Merck Sharp &amp; Dohme : antilipemics (2011)</li> </ul> <p><b>Additional Information declared:</b></p> <p>31/05/2013      No changes to declare in 2013</p>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Schaechinger Volker	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Boehringer-Ingelheim : Advisory board: Novel anticoagulants (2012)</li> <li>- Boston Scientific : Speaker fees: Stents (2012)</li> <li>- Orbus-Neich : Speaker fees: Stents (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>No additional information for the 2013 January - August period was submitted</p>
Scheen Andre	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Exenatide, Linagliptin (Diabetes) (2011-2012)</li> <li>- Sanofi Aventis : Insulin glargine (Diabetes) (2011-2012)</li> <li>- Boehringer-Ingelheim : Linagliptin (Diabetes) (2011-2012)</li> <li>- Novo-Nordisk : Liraglutide, New insulins (detemir, degludec) (Diabetes) (2011-2012)</li> <li>- Astra Zeneca : Saxagliptin (Diabetes) (2011-2012)</li> <li>- Bristol Myers Squibb : Saxagliptin (Diabetes) (2011-2012)</li> <li>- Merck Sharp &amp; Dohme : Sitagliptin (Diabetes) (2011-2012)</li> <li>- Novartis : Vildagliptin (Diabetes) (2011-2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Dapagliflozin (Diabetes) (2011-2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Unrestricted research grant related to diabetes (2011-2012)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Scheen Andre	<p><b>Additional Information declared:</b></p> <p>06/08/2013      same relationships as may 13 (no change to declare)</p>
Schirmer Henrik	<p>None</p> <p>No additional information for the 2013 January - August period was submitted</p>
Sirnes Per Anton	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- NORMA on behalf of Janssen Cilag : Invest fee CANVAS study (2012)</li> <li>- Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)</li> <li>- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012)</li> <li>- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012)</li> <li>- Merck Sharp &amp; Dohme : Investigator fee HPS2-THRIVE STUDY (2012)</li> <li>- Boehringer Ingelheim : Investigator Fee Reliable study (2012)</li> <li>- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)</li> <li>- Merck Sharp &amp; Dohme : investigator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2011)</li> <li>- GlaxoSmithKline : investigator fee, clinical study , SCAD (2011)</li> <li>- Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2011)</li> <li>- Jansen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011)</li> </ul> <p><b>Additional Information declared:</b></p> <p>No additional information for the 2013 January - August period was submitted</p>



## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Stromberg Anna	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Novartis : development of caregiverburden scale (2011-2012)</p> <p><b>Additional Information declared:</b></p> <p>14/05/2013 'same relationships as 2012 i.e. no changes to declare'</p>
Sudzhaeva Svetlana	<p>None</p> <p><b>Additional Information declared:</b></p> <p>15/05/2013 None</p> <p>07/08/2013 New information is absent</p>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)</p> <p>E - Research funding (personal). - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Viigimaa Margus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Coagulation (2011-2012)</li> <li>- GlaxoSmithKline : Coagulation (2011-2012)</li> <li>- Servier : Coronary heart disease (2011)</li> <li>- Merck Sharp &amp; Dohme : Dyslipidemia (2011-2012)</li> <li>- Boehringer-Ingelheim : Hypertension (2011-2012)</li> </ul>

## Guidelines on Diabetes 2013 (TF24) - Document Reviewers

Expert	Type of Relationship with Industry
Viigimaa Margus	<p>- Menarini : Hypertension (2011-2012)</p> <p><b>Additional Information declared:</b></p> <p>12/08/2013      No new information</p>
Vlachopoulos Charalambos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- Astra Zeneca : Statin (2011-2012)</p> <p>- Bayer : Testosterone (2012)</p> <p><b>Additional Information declared:</b></p> <p>05/06/2013      No changes to declare</p>
Xuereb Robert G	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <p>- None</p> <p>- Lilly : Principle Investigator TRILOGY-ACS (2012)</p> <p>- Lilly : Principle Investigator TRILOGY-ACS (2012)</p> <p><b>Additional Information declared:</b></p> <p>14/05/2013      Same relationships as 2012 i.e. no changes to declare.</p>

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CT (2012)</li> <li>- Servier : Imaging (2012)</li> <li>- Guerbet : Imaging (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013      Same relationships as last year, nothing new to declare.</p> <p>31/07/2013      NO new information</p>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>13/05/2013      no changes compared to 2012</p>
Bax Jeroen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Bax Jeroen	<ul style="list-style-type: none"> <li>- Edwards Lifesciences : Heart Valves (2012)</li> <li>- GE Healthcare : Imaging (2012)</li> <li>- Lantheus Inc : Imaging (2012)</li> <li>- Boston Scientific : Pacing (2012)</li> <li>- Medtronic : Pacing (2012)</li> <li>- St Jude Medical : Pacing (2012)</li> <li>- Biotronik : Pacing (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>23/06/2013      Nothing has changed</p>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2012)</li> <li>- Roche Pharma : Dalcetrapib (2012)</li> <li>- Novartis : Heart Failure and elinogrel (2012)</li> <li>- Daiichi Sankyo : Prasugrel (2012)</li> <li>- Eli Lilly : Prasugrel (2012)</li> <li>- Astra Zeneca : Ticagrelor (2012)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Ticagrelor (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013      No additional information to disclose in addition to my February 2013 disclosure</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Deaton M Christi	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)</p> <p><b>Additional Information declared:</b></p> <p>13/05/2013      Funding from Novo Nordisk has ended, no other changes to report</p> <p>13/05/2013      no other new information</p>
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012)</p> <p>C - Receipt of royalties for intellectual property. - Astra-Zeneca : Ticagrelor (2012)</p> <p><b>Additional Information declared:</b></p> <p>13/05/2013      Only the product of Menarini should be Olmesartan.</p> <p>06/08/2013      No change</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Fagard Robert	<p>None</p> <p><b>Additional Information declared:</b></p> <p>03/06/2013      No changes to declare</p> <p>07/08/2013      No changes to declare</p>
Ferrari Roberto	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulant and diabetes. Dagabitran (2012)</li> <li>- Medical Trials Analysis : Consultant in Clinical Trials (2012)</li> <li>- Servier : Myocardial ischemia and heart failure. Perindopril, ivabradine, amlodipine, trimetazidine (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Schering-Plough : Anti-platelet agent TRACER (2012)</li> <li>- Fondazione Salvatore Maugeri : General (2012)</li> <li>- Servier : Perindopril, ivabradine, amlodipine CLARify and SIGNify (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013      No new information</p>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> <li>- Boehringer-Ingelheim : Pradaxa (2012)</li> <li>- Bayer : Rivaroxiban (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Hasdai David	<p>- Astra Zeneca : Ticagrelor (2012)</p> <p><b>Additional Information declared:</b></p> <p>14/05/2013      none</p> <p>30/07/2013      speakers honorarium GSK</p>
Hoes Arno	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012)</p> <p>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</p> <p>D - Research funding (departmental or institutional). - I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012)</p> <p><b>Additional Information declared:</b></p> <p>03/06/2013      no changes to declare</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : cardiovascular (2012)</li> <li>- Boehringer-Ingelheim : cardiovascular (2012)</li> <li>- Daiichi Sankyo : cardiovascular (2012)</li> <li>- Medtronic : cardiovascular (2012)</li> <li>- Pfizer : cardiovascular (2012)</li> <li>- St Jude Medical : cardiovascular (2012)</li> <li>- Sanofi Aventis : cardiovascular (2012)</li> <li>- Meda pharma : cardiovascular (2012)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2012)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2012)</li> <li>- Bayer Healthcare : cardiovascular (2012)</li> <li>- Portola Pharmaceuticals : cardiovascular (2012)</li> <li>- BMS / Pfizer alliance : cardiovascular (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2012)</li> <li>- Sanofi Aventis : cardiovascular (2012)</li> <li>- Meda pharma : cardiovascular (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013      Consulting fees and honoraria 3M Medica</p>



## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	<p> MEDA Pharma  AstraZeneca  Bayer Healthcare  Biosense Webster  Boehringer Ingelheim  Daiichi-Sankyo  German Cardiac Society  MEDA Pharma  Medtronic  Merck  MSD  Otsuka Pharma  Pfizer / BMS  sanofi  Servier  Siemens  TAKEDA </p> <p> In addition, I have received travel support for meetings from the European Society of Cardiology (ESC), the European Heart Rhythm Association (EHRA), a registered branch of ESC, and from the German Atrial Fibrillation Competence NETwork (AFNET) </p> <p> Research Grants  3M Medica / MEDA Pharma  Cardiovascular Therapeutics  Medtronic  OMRON  SANOFI  St. Jude Medical  German Federal Ministry for Education and Research (BMBF)  Fondation Leducq </p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Kirchhof Paulus	German Research Foundation (DFG) European Union (EU)
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Lantheus Inc : Perfusion imaging tracer development (2012)</p> <p>D - Research funding (departmental or institutional). - Servier : Vascular inflammation (2012) - Athera : vascular inflammation (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet agents (2012) - Regado Biosciences : Antithrombotic agents (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2012)</p> <p>D - Research funding (departmental or institutional). - Edwards Lifesciences : Cardiac valves (2012) - Medtronic : Cardiac valves (2012) - St Jude Medical : Cardiac valves (2012) - Boston Scientific : Coronary stents (2012) - Siemens Healthcare : Medical imaging (2012) - Johnson &amp; Johnson : Thoracoscopic devices (2012)</p> <p><b>Additional Information declared:</b></p> <p>15/05/2013      same relationships as 2012 i.e. no changes to declare</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : Heart Failure (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Brilique (2012) - Servier : Coversyl (2012) - Abbott Vascular : MitraClip (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Linhart Ales	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Arterial hypertension (2012) - Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012) - GlaxoSmithKline : Atherosclerosis (2012) - Merck Sharp &amp; Dohme : Dyslipidemia (2012) - Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012) - Shire HGT : Fabry disease (2012) - Genzyme : Fabry disease (2012) - Actelion : Pulmonary hypertension (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Shire HGT : Fabry disease (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Nihoyannopoulos Petros	<p>None</p> <p>No additional information for the 2013 January - August period was submitted</p>
Piepoli Massimo Francesco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)</p> <p><b>Additional Information declared:</b></p> <p>13/05/2013 'same relationships as 2012 i.e. no changes to declare':</p> <p>30/07/2013 'same relationships as 2012 i.e. no changes to declare':</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- BMS : anticoagulant (2012)</li> <li>- Boehringer-Ingelheim : anticoagulant (2012)</li> <li>- Respicardia : anticoagulant (2012)</li> <li>- Abbott Vascular : devices (2012)</li> <li>- Amgen : heart failure (2012)</li> <li>- Novartis : heart failure (2012)</li> <li>- Johnson &amp; Johnson : heart failure (2012)</li> <li>- Bayer Healthcare : heart failure (2012)</li> <li>- Vifor Pharma Ltd : heart failure (2012)</li> <li>- Corthera : heart failure (2012)</li> <li>- Coridea : heart failure (2012)</li> <li>- Pfizer : heart failure, anticoagulant (2012)</li> <li>- Servier : heart failure, coronary artery disease (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vifor Pharma Ltd : heart failure (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>14/05/2013      update to DOI 2012:                             - Abbott Vascular</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Sirnes Per Anton	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - None</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  - NORMA on behalf of Janssen Cilag : Invest fee CANVAS study (2012)  - Quintiles on behalf of Novartis : Invest fee CANTOS study (2012)  - GlaxoSmithKline : Invest fee HZC113108 and LPL100601 studies (2012)  - SticaresInterACt on behalf of Servier : Invest fee SIGNIFY study (2012)  - Merck Sharp &amp; Dohme : Investigator fee HPS2-THRIVE STUDY (2012)  - Boehringer Ingelheim : Investigator Fee Relyable study (2012)  - Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)</p> <p><b>Additional Information declared:</b>  No additional information for the 2013 January - August period was submitted</p>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  - sanofi-aventis : Dronedarone-antiarrhythmic agent (2012)</p> <p>E - Research funding (personal).  - Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)</p> <p>No additional information for the 2013 January - August period was submitted</p>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  - Bayer : Aspirin, Rivaroxaban (2012)  - Amgen : Darbopietin (2012)  - Servier : Ivabradine, Phase II investigational products (2012)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.  - Servier : Ivabradine, Phase II investigational products (2012)</p>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
	<p><b>Additional Information declared:</b></p> <p>13/05/2013      No new info.</p>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cardiomems : implanted pulmonary artery pressure sensor (2012)</li> <li>- United Therapeutics : Pulmonary arterial hypertension (2012)</li> <li>- GSK : pulmonary arterial hypertension - ambrisentan (2012)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012)</li> <li>- Lilly : pulmonary arterial hypertension - tadalafil (2012)</li> <li>- AOP : Pulmonary arterial hypertension - treprostinil (2012)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2012)</li> <li>- Bristol Myers Squibb : thromboembolic disease - Apixaban (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2012)</li> <li>- Sanofi Aventis : Thromboembolic disease (2012)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>
Wijns William	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- None</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosensors : device (2012)</li> <li>- Boston Scientific : device (2012)</li> <li>- Edwards Lifesciences : device (2012)</li> <li>- Medtronic : device (2012)</li> <li>- St Jude Medical : device (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> <li>- Biotronik : device (2012)</li> <li>- Terumo Inc : device (2012)</li> <li>- Abbott Vascular : device (2012)</li> <li>- Cordis : device (2012)</li> <li>- Orbus Nech : device (2012)</li> <li>- MICELL : device (2012)</li> <li>- Vessix : device (2012)</li> <li>- Tryton : device (2012)</li> <li>- GlaxoSmithKline : drug (2012)</li> <li>- Astra Zeneca : pharma (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Cardio3 Biosciences : cell therapy (2012)</li> <li>- Boston Scientific : device (2012)</li> <li>- Medtronic : device (2012)</li> <li>- St Jude Medical : device (2012)</li> <li>- Biotronik : device (2012)</li> <li>- Abbott Laboratories : device (2012)</li> <li>- MICELL : device (2012)</li> <li>- Therabel : drug (2012)</li> </ul> <p>No additional information for the 2013 January - August period was submitted</p>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet drug (2012)</li> <li>- Eli Lilly : Antiplatelet drug (2012)</li> <li>- Abbott : Stent (2012)</li> <li>- Biosensors : Stent (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Boston Scientific : Stent (2012)</li> <li>- Medtronic : Stent (2012)</li> <li>- Biotronik : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- Edwards Lifesciences : TAVI (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : OCT (2012)</li> <li>- Abbott : Stent (2012)</li> <li>- Biosensors : Stent (2012)</li> <li>- Medtronic : Stent (2012)</li> <li>- Biotronik : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> </ul> <p><b>Additional Information declared:</b></p> <p>31/07/2013      same declaration as before and no changes</p>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Help in Design Echocardiographic protocol (2012)</li> <li>- Merck Sharp &amp; Dohme : Lecture (2012)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- FP7 EU research program : CV Imaging (2012)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2012)</li> </ul>



## Committee for Practice Guidelines 2012-2014

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<b>Additional Information declared:</b>  13/05/2013      Same

This table represents the relevant relationships of the above experts with Industries and other entities that were reported to us at the time of publication of the Guidelines.